• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human psychopharmacology: clinical and experimental >Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
【24h】

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.

机译：文拉法辛ER社会患者的效果焦虑症:双盲,安慰剂对照,与这些相应平行的组织比较帕罗西汀。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study evaluated the anxiolytic efficacy, safety and tolerability of a flexible dose of venlafaxine extended release (ER) compared with placebo and paroxetine in the short-term treatment of generalized social anxiety disorder (SAD). Adult outpatients with generalized SAD (n = 434) were randomized to receive capsules of venlafaxine ER 75 mg to 225 mg/day, paroxetine 20 mg to 50 mg/day, or placebo for 12 weeks. The primary efficacy variable was the Liebowitz social anxiety scale total score. Secondary efficacy variables included the patient-rated social phobia inventory and the proportion of responders in each group (a responder was defined as having a clinical global impression-improvement score of 1 or 2). Treatment with venlafaxine ER was associated with significantly greater improvement than treatment with placebo for all primary and secondary efficacy variables (p < 0.05). No significant differences in primary or secondary efficacy variables were observed between the venlafaxine ER and paroxetine groups. The week 12 response rates were 69%, 66% and 36% for the venlafaxine ER, paroxetine and placebo groups, respectively. Both active treatments were generally well tolerated and were associated with a similar incidence of adverse events. This study shows that venlafaxine ER is an effective, safe and well-tolerated drug treatment for SAD. Copyright 2004 John Wiley & Sons, Ltd.
机译：本研究评估抗焦虑的疗效,一个灵活的剂量的安全性和耐受性文拉法辛延长释放(ER)相比在短期内安慰剂,帕罗西汀治疗广泛性社交焦虑障碍(SAD)。= 434)被随机分配接受胶囊的文拉法辛ER 75毫克到225毫克/天,帕罗西汀20毫克到50毫克/天,12周或安慰剂。主要功效Liebowitz变量社交焦虑量表总分。包括患者自我评分疗效变量社交恐惧症库存和的比例每组人员(一个应答器的定义全球临床impression-improvement 1或2的得分)。文拉法辛治疗ER是相关联的明显比治疗更大的改进与所有主要和次要的安慰剂疗效变量(p < 0.05)。主要或次要疗效的差异变量之间的观察文拉法辛ER和帕罗西汀组。文拉法辛的利率分别为69%、66%和36%呃,帕罗西汀和安慰剂组,分别。积极的治疗都是一般容忍,被关联到一个类似的不良事件的发生率。文拉法辛是一种有效的,安全的良好的药物治疗悲伤。2004年约翰·威利& Sons有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号